|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||94.76 - 95.86|
|52-week range||94.76 - 95.86|
|Beta (5Y monthly)||1.54|
|PE ratio (TTM)||27.04|
|Earnings date||01 Nov 2021 - 05 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Emerson (EMR) is poised to gain from strength across its end markets, acquisitions, and shareholder-friendly policies. However, rising costs and high debt-level remain concerning.
Emerson (EMR) is well poised to benefit from strength across its end markets, acquired assets, and shareholder-friendly policies.
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...